ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$171.46 |
| 52 Week High | US$191.82 |
| 52 Week Low | US$126.40 |
| Beta | 0.61 |
| 11 Month Change | -2.01% |
| 3 Month Change | -2.29% |
| 1 Year Change | 35.22% |
| 33 Year Change | 64.61% |
| 5 Year Change | 117.04% |
| Change since IPO | 105.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABBV | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 9.0% | 3.8% | -0.6% |
| 1Y | 35.2% | 6.0% | 2.5% |
Return vs Industry: ABBV exceeded the Austrian Biotechs industry which returned 6% over the past year.
Return vs Market: ABBV exceeded the Austrian Market which returned 2.5% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: ABBV's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: ABBV's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | €300.28b |
| Earnings (TTM) | €4.88b |
| Revenue (TTM) | €53.33b |
61.5x
P/E Ratio5.6x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$55.53b |
| Cost of Revenue | US$16.47b |
| Gross Profit | US$39.06b |
| Other Expenses | US$33.98b |
| Earnings | US$5.08b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 70.33% |
| Net Profit Margin | 9.15% |
| Debt/Equity Ratio | 1,174.8% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield216%
Payout RatioDoes ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Jan 15 2025 |
| Dividend Pay Date | Feb 14 2025 |
| Days until Ex dividend | 51 days |
| Days until Dividend pay date | 81 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks